Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Pasquale Rescigno

Newcastle AuthorsTitleYearFull text
Dr Pasquale Rescigno
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study2025
Dr Pasquale Rescigno
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care2025
Dr Pasquale Rescigno
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study2024
Dr Pasquale Rescigno
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)2024
Dr Pasquale Rescigno
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”2024
Dr Pasquale Rescigno
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies2024
Dr Pasquale Rescigno
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial2024
Dr Pasquale Rescigno
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer2024
Professor Alastair Greystoke
Professor Ruth Plummer
Dr Christoph Oing
Dr Pasquale Rescigno
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis2024
Dr Pasquale Rescigno
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations2024
Dr Christoph Oing
Dr Pasquale Rescigno
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review2024
Dr Pasquale Rescigno
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study2024
Dr Pasquale Rescigno
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)2024
Dr Pasquale Rescigno
Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma2024
Dr Pasquale Rescigno
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study2024
12345